Brinzolamide

Modify Date: 2024-01-02 08:05:36

Brinzolamide Structure
Brinzolamide structure
Common Name Brinzolamide
CAS Number 138890-62-7 Molecular Weight 383.507
Density 1.5±0.1 g/cm3 Boiling Point 586.0±60.0 °C at 760 mmHg
Molecular Formula C12H21N3O5S3 Melting Point N/A
MSDS Chinese USA Flash Point 308.2±32.9 °C

 Use of Brinzolamide


Brinzolamide(AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.Target: carbonic anhydrase IIBrinzolamide (< 1 mg) ophthalmic suspension lowers intraocular pressure in Dutch-belted pigmented rabbits in a dose-dependent manner with an onset within 0.5 hour and a peak response by 1-2 hours. Brinzolamide (0.6 mg) ophthalmic suspension lowers intraocular pressure in laser-treated glaucomatous cynomolgus monkeys in a dose-dependent manner with an onset within 1 hour and a peak response by 3 hours. Brinzolamide dosages of 30 mg/kg, produces a 44% reduction in intestinal charcoal meal progression, but 1 and 10 mg/kg produced 8% and 18% decreases, respectively, in male CD-1 mice. Brinzolamide of 1 mg/kg, 10 mg/kg, and 30 mg/kg prolongs barbiturate sleep time by 57%, 15%, and 35%, respectively, in male CD-1 mice [1]. Brinzolamide (< 3%) produces significantly greater mean percent intraocular pressure reductions and mean intraocular pressure reductions compared with placebo in patients with primary, open-angle glaucoma or ocular hypertension. The optimal intraocular pressure-lowering concentration of brinzolamide is 1%, brinzolamide 1% is well tolerated by patients with primary open-angle glaucoma or ocular hypertension when administered twice daily [2].

 Names

Name brinzolamide
Synonym More Synonyms

 Brinzolamide Biological Activity

Description Brinzolamide(AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.Target: carbonic anhydrase IIBrinzolamide (< 1 mg) ophthalmic suspension lowers intraocular pressure in Dutch-belted pigmented rabbits in a dose-dependent manner with an onset within 0.5 hour and a peak response by 1-2 hours. Brinzolamide (0.6 mg) ophthalmic suspension lowers intraocular pressure in laser-treated glaucomatous cynomolgus monkeys in a dose-dependent manner with an onset within 1 hour and a peak response by 3 hours. Brinzolamide dosages of 30 mg/kg, produces a 44% reduction in intestinal charcoal meal progression, but 1 and 10 mg/kg produced 8% and 18% decreases, respectively, in male CD-1 mice. Brinzolamide of 1 mg/kg, 10 mg/kg, and 30 mg/kg prolongs barbiturate sleep time by 57%, 15%, and 35%, respectively, in male CD-1 mice [1]. Brinzolamide (< 3%) produces significantly greater mean percent intraocular pressure reductions and mean intraocular pressure reductions compared with placebo in patients with primary, open-angle glaucoma or ocular hypertension. The optimal intraocular pressure-lowering concentration of brinzolamide is 1%, brinzolamide 1% is well tolerated by patients with primary open-angle glaucoma or ocular hypertension when administered twice daily [2].
Related Catalog
References

[1]. DeSantis, L., Preclinical overview of brinzolamide. Surv Ophthalmol, 2000. 44 Suppl 2: p. S119-29.

[2]. Silver, L.H., Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Surv Ophthalmol, 2000. 44 Suppl 2: p. S147-53.

 Chemical & Physical Properties

Density 1.5±0.1 g/cm3
Boiling Point 586.0±60.0 °C at 760 mmHg
Molecular Formula C12H21N3O5S3
Molecular Weight 383.507
Flash Point 308.2±32.9 °C
Exact Mass 383.064331
PSA 163.80000
LogP -0.65
Vapour Pressure 0.0±1.6 mmHg at 25°C
Index of Refraction 1.626
Storage condition ?20°C

 Safety Information

Hazard Codes Xi
Risk Phrases R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S26-S36
RIDADR NONH for all modes of transport
RTECS XJ9095055
HS Code 2935009090

 Synthetic Route

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: WO2008/62463 A2, ; Page/Page column 26-27 ;

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: US2010/9977 A1, ; Page/Page column 12 ;

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: BIOCON LIMITED; KOTHAKONDA, Kiran Kumar; VENKATA, Srinivas Pullela; RAJMAHENDRA, Shanmughasamy; MHETRE, Sandeep Madhukar; CHANDAVARKAR, Arun Patent: WO2013/114397 A2, 2013 ; Location in patent: Page/Page column 7; 10 ;

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: BIOCON LIMITED; KOTHAKONDA, Kiran Kumar; VENKATA, Srinivas Pullela; RAJMAHENDRA, Shanmughasamy; MHETRE, Sandeep Madhukar; CHANDAVARKAR, Arun Patent: WO2013/114397 A2, 2013 ; Location in patent: Page/Page column 7; 9 ;

~48%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: USV LIMITED Patent: WO2008/62463 A2, 2008 ; Location in patent: Page/Page column 29-30 ;

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: EP2348026 A1, ;

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: Organic Process Research and Development, , vol. 3, # 2 p. 114 - 120

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: Organic Process Research and Development, , vol. 3, # 2 p. 114 - 120

~%

Brinzolamide Structure

Brinzolamide

CAS#:138890-62-7

Literature: Organic Process Research and Development, , vol. 3, # 2 p. 114 - 120

 Customs

HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

 Articles39

More Articles
Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.

J. Liposome Res. 24(3) , 171-81, (2014)

The purpose of the present study was to optimize methazolamide (MTZ)-loaded solid lipid nanoparticles (SLNs) which were used as topical eye drops by evaluating the relationship between design factors ...

Soluble CD44 and vascular endothelial growth factor levels in patients with acute primary angle closure.

Acta Ophthalmol. 93 , e261-5, (2015)

Acute elevation of intraocular pressure (IOP) in acute primary angle closure (APAC) can cause huge damage to the variable cells in the eye; however, the mechanisms that connect the two processes still...

Meta-analysis of α2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy.

Curr. Med. Res. Opin. 28(4) , 543-50, (2012)

To evaluate the efficacy of α2-adrenergic agonist (AA) brimonidine and topical carbonic anhydrase inhibitors (CAIs) dorzolamide and brinzolamide in reducing intraocular pressure (IOP) when used as adj...

 Synonyms

MFCD08067749
Birnzolamide
Brinzolamide (BRZ)
3znc
Azopt (TN)
(4R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
(R)-(+)-4-ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
(4R)-4-(Ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Azopt
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4R)-
Brinzolamide [USAN]
Brinzolamide
Top Suppliers:I want be here




Get all suppliers and price by the below link:

Brinzolamide suppliers


Price: $66/10mM*1mLinDMSO

Reference only. check more Brinzolamide price